Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Return on Sales (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Return on Sales for 10 consecutive years, with 520.2% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Sales fell 61272.0% year-over-year to 520.2%, compared with a TTM value of 520.2% through Sep 2025, down 51049.0%, and an annual FY2024 reading of 79.66%, down 6326.0% over the prior year.
  • Return on Sales was 520.2% for Q3 2025 at Avalo Therapeutics, down from 104.8% in the prior quarter.
  • Across five years, Return on Sales topped out at 165.56% in Q1 2025 and bottomed at 520.2% in Q3 2025.
  • Average Return on Sales over 5 years is 42.5%, with a median of 6.53% recorded in 2021.
  • Peak annual rise in Return on Sales hit 26417bps in 2025, while the deepest fall reached -61272bps in 2025.
  • Year by year, Return on Sales stood at 0.3% in 2021, then skyrocketed by 99bps to 0.0% in 2022, then plummeted by -376461bps to 14.3% in 2023, then plummeted by -1187bps to 184.06% in 2024, then plummeted by -183bps to 520.2% in 2025.
  • Business Quant data shows Return on Sales for AVTX at 520.2% in Q3 2025, 104.8% in Q2 2025, and 165.56% in Q1 2025.